Literature DB >> 32115665

Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal.

Daniel Lopez-Castillo1, Alvaro March-Rodriguez, Alejo Rodriguez-Vida, Ramon M Pujol, Sonia Segura.   

Abstract

Entities:  

Keywords:  calcinosis cutis; digital ulcers; hyperphosphatemia; inhibitor; skin adverse reaction; fibroblast growth factor receptor

Mesh：

Substances：

Year:  2020        PMID： 32115665      PMCID： PMC9128941          DOI： 10.2340/00015555-3438

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  13 in total

1.  Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction.

Authors:  Gina M Yanochko; Allison Vitsky; Jonathan R Heyen; Brad Hirakawa; Justine L Lam; Jeff May; Tim Nichols; Frederick Sace; Dusko Trajkovic; Eileen Blasi
Journal:  Toxicol Sci       Date:  2013-07-20       Impact factor: 4.849

2.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Authors:  Milind Javle; Maeve Lowery; Rachna T Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J Borad; Ramesh K Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do-Youn Oh; Philip A Philip; Li-Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun-Huei Yeh; Kristen Ciombor; Richard S Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X Zhu; Ghassan K Abou-Alfa; Tanios Bekaii-Saab
Journal:  J Clin Oncol       Date:  2017-11-28       Impact factor: 44.544

3.  Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

Authors:  Sarah Bétrian; Carlos Gomez-Roca; Emmanuelle Vigarios; Jean Pierre Delord; Vincent Sibaud
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

4.  Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor.

Authors:  David R Carr; Llana Pootrakul; Hui-Zi Chen; Catherine G Chung
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

Review 5.  Calcinosis cutis: part I. Diagnostic pathway.

Authors:  Nadine Reiter; Laila El-Shabrawi; Bernd Leinweber; Andrea Berghold; Elisabeth Aberer
Journal:  J Am Acad Dermatol       Date:  2011-07       Impact factor: 11.527

Review 6.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

7.  Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Authors:  Martin Schuler; Byoung Chul Cho; Cyrus Michael Sayehli; Alejandro Navarro; Ross A Soo; Heike Richly; Philippe Alexandre Cassier; David Tai; Nicolas Penel; Lucia Nogova; Se Hoon Park; Martin Schostak; Pablo Gajate; Richard Cathomas; Prabhu Rajagopalan; Joachim Grevel; Sebastian Bender; Oliver Boix; Hendrik Nogai; Matthias Ocker; Peter Ellinghaus; Markus Joerger
Journal:  Lancet Oncol       Date:  2019-08-09       Impact factor: 41.316

8.  A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Authors:  Martin H Voss; Cinta Hierro; Rebecca S Heist; James M Cleary; Funda Meric-Bernstam; Josep Tabernero; Filip Janku; Leena Gandhi; A John Iafrate; Darrell R Borger; Nobuya Ishii; Youyou Hu; Yulia Kirpicheva; Valerie Nicolas-Metral; Anna Pokorska-Bocci; Anne Vaslin Chessex; Claudio Zanna; Keith T Flaherty; Jose Baselga
Journal:  Clin Cancer Res       Date:  2019-02-11       Impact factor: 13.801

9.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

Authors:  Yohann Loriot; Andrea Necchi; Se Hoon Park; Jesus Garcia-Donas; Robert Huddart; Earle Burgess; Mark Fleming; Arash Rezazadeh; Begoña Mellado; Sergey Varlamov; Monika Joshi; Ignacio Duran; Scott T Tagawa; Yousef Zakharia; Bob Zhong; Kim Stuyckens; Ademi Santiago-Walker; Peter De Porre; Anne O'Hagan; Anjali Avadhani; Arlene O Siefker-Radtke
Journal:  N Engl J Med       Date:  2019-07-25       Impact factor: 91.245

10.  Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Authors:  Vincenzo Mazzaferro; Bassel F El-Rayes; Michele Droz Dit Busset; Christian Cotsoglou; William P Harris; Nevena Damjanov; Gianluca Masi; Lorenza Rimassa; Nicola Personeni; Fadi Braiteh; Vittorina Zagonel; Kyriakos P Papadopoulos; Terence Hall; Yunxia Wang; Brian Schwartz; Julia Kazakin; Sherrie Bhoori; Filippo de Braud; Walid L Shaib
Journal:  Br J Cancer       Date:  2018-11-13       Impact factor: 7.640
View more
  1 in total

1.  Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.

Authors:  Akshan Puar; Diane Donegan; Paul Helft; Matthew Kuhar; Jonathan Webster; Megana Rao; Michael Econs
Journal:  AACE Clin Case Rep       Date:  2022-07-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.